Relay Therapeutics Inc. (RLAY)
RLAY trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1812364/000119312526076739/0001193125-26-076739-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | RLAY on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001812364 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $15.4M |
| Net income | -$276.5M |
| Operating income | -$302.7M |
| Net margin | -1800.6% |
| Operating margin | -1971.6% |
| Revenue growth | +53.4% |
| Cash | $84.0M |
| Total assets | $621.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 248.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $124.2M cash; operating cash flow -$53.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 220,959,470 (2026-10-30); 173,322,385 a year earlier; 123,268,740 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-08-06 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-10 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $129.0M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $0 | -$81.7M | -$63.9M | $124.2M | No debt tags | $10.3M | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $350K | -$83.7M | -$54.1M | $121.2M | No debt tags | $10.3M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $3.0M | -$73.3M | -$51.1M | $204.6M | No debt tags | $10.7M | 10-Q 2026-05-05 |
| Q4 2025 2025-12-31 | $7.0M | -$54.9M | -$44.9M | $84.0M | No debt tags | $15.4M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $0 | -$74.1M | -$62.1M | $91.6M | No debt tags | $8.4M | 10-Q 2025-11-06 |
| Q2 2025 2025-06-30 | $677K | -$70.4M | -$55.3M | $113.9M | No debt tags | $8.4M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $7.7M | -$77.1M | -$73.2M | $93.5M | No debt tags | $7.7M | 10-Q 2026-05-05 |
| Q4 2024 2024-12-31 | $0 | -$76.0M | -$57.9M | $124.3M | No debt tags | $10.0M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-08-06 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 557 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.7% |
| 1 month | +4.2% |
| 3 months | -9.2% |
| Year to date | +113.8% |
| 1 year | +180.5% |
| From 52-week high | -12.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TARS | Tarsus Pharmaceuticals Inc. | $78.68 | -1.99% | $3.9B |
| CRSP | CRISPR Therapeutics AG Common Shares | $40.37 | -4.43% | $3.9B |
| IOVA | Iovance Biotherapeutics Inc. | $7.55 | -2.71% | $3.5B |
| ADPT | Adaptive Biotechnologies Corporation | $27.87 | -4.03% | $4.5B |
| ADMA | ADMA Biologics Inc | $13.47 | -1.54% | $3.0B |
| VCEL | Vericel Corporation | $57.48 | +0.91% | $2.9B |
| DNLI | Denali Therapeutics Inc. | $18.08 | -3.52% | $2.9B |
| SRRK | Scholar Rock Holding Corporation | $44.54 | +3.09% | $5.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier